Xiangsheng Zuo, M.D., Ph.D.
Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine
About Dr. Zuo
Research Interests: Colorectal cancer is the second leading cause of cancer deaths in the United States and novel chemopreventive modalities are great ly needed. 15-Lipoxygenase-1 (15-LOX-1) is down-regulated in various human cancers, such as esophageal, breast, and pancreatic cancers. 15-LOX-1 re-expression via pharmaceutical agents or adenoviral vectors induces growth inhibition and reestablishes terminal differentiation and apoptosis in cancer cells. My major research interests are to define the mechanisms of 15-LOX-1 transcription silencing in cancer cells and develop interventions to molecularly target 15-LOX-1 transcriptional silencing to suppress colonic tumorigenesis.
Read More
Present Title & Affiliation
Primary Appointment
Assistant Professor, Department of Gastrointestinal (GI) Medical Oncology - Research, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Research Interests
15-Lipoxygenase Colon Cancer Colonic Tumorigenesis Chemoprevention
Education & Training
Degree-Granting Education
| 2001 | Shanghai Jiao-Tong University Medical School, Shanghai, CHN, PHD, Endocrinology |
| 1990 | Anhui Medical University, Anhui, CHN, MS, Pathophysiology |
| 1987 | Bengbu Medical College, Anhui, CHN, MD, Medicine |
Experience & Service
Academic Appointments
Assistant Professor, Department of Clinical Cancer Prevention, Division of OVP, Cancer Prevention and Population Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX, 2010 - 2011
Instructor, Department of Clinical Cancer Prevention, Division of OVP, Cancer Prevention and Population Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX, 2006 - 2010
Postdoctoral Fellow, Department of Clinical Cancer Prevention, Division of OVP, Cancer Prevention and Population Sciences, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 2002 - 2006
Associate Professor, First Affiliated Hospital of Anhui Medical University, Hefei, 1996 - 2001
Assistant Professor, First Affiliated Hospital of Anhui Medical University, Hefei, 1993 - 1996
Instructor, First Affiliated Hospital of Anhui Medical University, Hefei, 1990 - 1993
Other Appointments/Responsibilities
Departmental Faculty Search Committee Member, The University of Texas MD Anderson Cancer Center, Houston, TX, 2009 - 2011
Selected Publications
Peer-Reviewed Articles
- Wei D, Wang L, Zuo X, Bresalier RS. Vitamin D: Promises on the Horizon and Challenges Ahead for Fighting Pancreatic Cancer. Cancers (Basel) 13(11), 2021. e-Pub 2021. PMID: 34072725.
- Liu F, Zuo X, Liu Y, Deguchi Y, Moussalli MJ, Chen W, Yang P, Wei B, Tan L, Lorenzi PL, Gao S, Jaoude JC, Mehdizadeh A, Valentin LA, Wei D, Shureiqi I. Suppression of Membranous LRP5 Recycling, Wnt/β-Catenin Signaling, and Colon Carcinogenesis by 15-LOX-1 Peroxidation of Linoleic Acid in PI3P. Cell Rep 32(7):108049, 2020. PMID: 32814052.
- Liu Y, Colby JK, Zuo X, Jaoude J, Wei D, Shureiqi I. The Role of PPAR-δ in Metabolism, Inflammation, and Cancer: Many Characters of a Critical Transcription Factor. Int J Mol Sci 19(11), 2018. e-Pub 2018. PMID: 30373124.
- Zuo X, Shureiqi I. Eicosanoid profiling in colon cancer: Emergence of a pattern. Prostaglandins Other Lipid Mediat 104-105:139-43, 2013. e-Pub 2012. PMID: 22960430.
- Xu M, Zuo X, Shureiqi I. Targeting peroxisome proliferator-activated receptor-β/δ in colon cancer: How to aim?. Biochem Pharmacol 85(5):607-11, 2013. e-Pub 2012. PMID: 23041232.
- Zuo X, Peng Z, Wu Y, Moussalli MJ, Yang XL, Wang Y, Parker-Thornburg J, Morris JS, Broaddus RR, Fischer SM, Shureiqi I. Effects of gut-targeted 15-LOX-1 transgene expression on colonic tumorigenesis in mice. J Natl Cancer Inst 104(9):709-16, 2012. e-Pub 2012. PMID: 22472308.
- Il Lee S, Zuo X, Shureiqi I. 15-Lipoxygenase-1 as a tumor suppressor gene in colon cancer: is the verdict in?. Cancer Metastasis Rev 30(3-4):481-91, 2011. PMID: 22037943.
- Shureiqi I, Chen D, Day RS, Zuo X, Hochman FL, Ross WA, Cole RA, Moy O, Morris JS, Xiao L, Newman RA, Yang P, Lippman SM. Profiling Lipoxygenase Metabolism in Specific Steps of Colorectal Tumorigenesis. Cancer Prev Res (Phila) 3(7):829-38, 2010. e-Pub 2010. PMID: 20570882.
- Moussalli M, Lotan R, Zuo X, Wu Y, Logsdon C, Morris JS Shureiqi. Ubiquitous Loss of 15-Lipoxygenase-1 Expression in Cancer Cells and Terminal Cell Differentiation Evasion (under revision). Cancer Research, 2010.
- Zuo X, Peng Z, Moussalli MJ, Morris JS, Broaddus RR, Fischer SM, Shureiqi I. Targeted genetic disruption of peroxisome proliferator-activated receptor-delta and colonic tumorigenesis. J Natl Cancer Inst 101(10):762-7, 2009. e-Pub 2009. PMID: 19436036.
- Zuo X, Morris JS, Broaddus R, Shureiqi I. 15-LOX-1 transcription suppression through the NuRD complex in colon cancer cells. Oncogene 28(12):1496-505, 2009. e-Pub 2009. PMID: 19198625.
- Zuo X, Morris JS, Shureiqi I. Chromatin modification requirements for 15-lipoxygenase-1 transcriptional reactivation in colon cancer cells. J Biol Chem 283(46):31341-7, 2008. e-Pub 2008. PMID: 18799463.
- Zuo X, Shen L, Issa JP, Moy O, Morris JS, Lippman SM, Shureiqi I. 15-Lipoxygenase-1 transcriptional silencing by the DNA methyltransferase-1 independently of DNA methylation. FASEB J 22(6):1981-92, 2008. e-Pub 2008. PMID: 18198215.
- Shureiqi I, Zuo X, Broaddus R, Wu Y, Guan B, Morris JS, Lippman SM. The transcription factor GATA-6 is overexpressed in vivo and contributes to silencing 15-LOX-1 in vitro in human colon cancer. FASEB J 21(3):743-53, 2007. e-Pub 2006. PMID: 17167069.
- Zuo X, Wu Y, Morris JS, Stimmel JB, Leesnitzer LM, Fischer SM, Lippman SM, Shureiqi I. Oxidative metabolism of linoleic acid modulates PPAR-beta/delta suppression of PPAR-gamma activity. Oncogene 25(8):1225-1241, 2006. PMID: 16288226.
- Shureiqi I, Jiang W, Zuo X, Wu Y, Stimmel JB, Leesnitzer LM, Morris JS, Fan HZ, Fischer SM, Lippman SM. The 15-lipoxygenase-1 product 13-S-hydroxyoctadecadienoic acid down-regulates PPAR-delta to induce apoptosis in colorectal cancer cells. Proc Natl Acad Sci U S A 100(17):9968-9973, 2003. e-Pub 2003. PMID: 12909723.
- Zuo X, Li G, Luo T, Li J, Xiu Y, Sun W, and Luo M.. Differentiation of NIH3T3 fibroblasts into adipocytes induced by PPAR2 expression [in English]. Chin Med J 114(9):916-920, 2001. PMID: 11780381.
- Yang P, Zuo X, Advani S, Wei B, Malek J, Day RS, Shureiqi I. Celecoxib Colorectal Bioavailability and Chemopreventive Response in Familial Adenomatous Polyposis Patients. Cancer Prev Res (Phila). e-Pub 2021. PMID: 34610992.
Abstracts
- Moussalli M, Wu Y, Zuo X, Yang XL, Wistuba II, Raso MG, Morris JS, Bowser JL, Minna JD, Lotan R, Shureiqi S. Terminal Cell Differentiation Evasion in Cancer Cells through Ubiquitous 15-Lipoxygenase-1 Expression Loss. 12th International Conference of Eicosanoids and Other Bioactive Lipids in Cancer, Inflammation and Related Diseases, 2011.
Grant & Contract Support
| Title: | Molecular Understanding and Targeting of Determinant Factors in Gastric Tumorigenesis |
| Funding Source: | NIH/NCI |
| Role: | Principal Investigator |
| Title: | ω-3 fatty acid-derived mediators promote resolution of inflammation: Uncovering new strategies for preventing colitis-associated colon cancer |
| Funding Source: | NIH/NCI |
| Role: | Investigator |
| Title: | The critical role of PPAR-d in gastric inflammation and carcinogenesis |
| Funding Source: | TMC DDC foundation |
| Role: | Principal Investigator |